• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Immunol . Vaccine immunity can drive eosinophil recruitment in influenza breakthrough infection with mouse strain-specific outcomes

tetano

Editor, Senior Moderator
J Immunol

. 2026 Oct 1;215(10):vkag279.
doi: 10.1093/jimmun/vkag279.

Vaccine immunity can drive eosinophil recruitment in influenza breakthrough infection with mouse strain-specific outcomes​


Lauren A Chang 1 2 3 , Eleanor Burgess 1 2 3 , Moataz Noureddine 1 2 3 , Anthony J Wells 4 , Johanna Vandekerckhove 1 3 , Juan García-Bernalt Diego 1 3 , Brett T Webb 5 , Leonie J Grüneberg 1 3 , Seok-Chan Park 1 3 , Gabriel Laghlali 1 3 , Vivian Yan 1 2 3 , Farah El-Ayache 1 3 , Bart N Lambrecht 6 7 8 , Pamela T Wong 9 10 11 , Amali E Samarasinghe 4 12 , Michael Schotsaert 1 3 13 14 15

Affiliations Expand


Abstract​


Eosinophils are pleiotropic cells and can respond to a wide array of inflammatory stimuli, including respiratory viral infection. Although they are historically associated with adverse outcomes in vaccinated hosts after breakthrough infection, such as during vaccine-associated enhanced respiratory disease (VAERD) for respiratory syncytial virus (RSV), eosinophils can also help mediate antiviral immunity. We previously observed mild, nonpathological lung eosinophilia in vaccinated mice experiencing influenza breakthrough infection, distinct from VAERD. Here, we investigated the factors driving this eosinophil recruitment and their contribution to host outcomes during influenza breakthrough infection. Vaccine-elicited Abs partially mediate eosinophil recruitment to the lungs during infection but do not confer full protection against viral replication or disease. Live viral replication was needed for robust eosinophil recruitment. Furthermore, both CD4 and CD8 T cells were required for optimal eosinophil accumulation in the lungs. Intramuscular vaccination resulted in the induction of a balanced type 1/2 response in the spleen and mainly a type 2 response in the lung upon infection, whereas a type 1 immune response dominated in the lungs of unvaccinated mice upon infection. Eosinophil depletion studies revealed strain-dependent effects: in BALB/c mice, eosinophil depletion did not significantly affect morbidity, viral load, lung inflammation, or lung lesion severity. However, in C57BL/6 mice, eosinophil depletion improved viral control and reduced pro-inflammatory cytokine expression. Our findings highlight the complex interplay among vaccine-induced immunity, eosinophil recruitment, and host genetic background in shaping outcomes during influenza breakthrough infection, with implications for vaccine strategies and immunopathology mitigation in diverse populations.

Keywords: cytokines; eosinophil; influenza virus; type 2 immunity; vaccine.
 
Back
Top Bottom